Ask three sales leaders which methodology they run and you'll often get a religious war: SPIN people quietly disdain Challenger people, MEDDIC people think everyone else is sloppy, and someone in the corner is still defending solution selling. The fight is usually a category error. These four frameworks aren't competing answers to the same question, they answer different questions, at different stages of a deal. Treat them as a toolkit, not a creed, and most of the argument disappears.

The quick version

  • SPIN is a questioning method, how to run a sales conversation so the buyer talks themselves into the problem.
  • Solution selling is a diagnose-then-prescribe approach, uncover a need, map your product to it.
  • Challenger is a teaching stance, reframe how the buyer sees their problem instead of waiting for them to define it.
  • MEDDIC isn't a way to talk to buyers at all, it's a qualification checklist for deciding which deals are real and worth your time.

The idea in depth

The cleanest way to understand these four is to stop treating them as a menu and start treating them as a timeline. Early in a deal you need to qualify (is this real?) and diagnose (what's actually wrong?). Later you need to differentiate (why us?) and control the process (how does this close?). Each framework lives mostly in one of those zones.

flowchart LR
  A(["Qualify the deal"]) --> B(["Diagnose the need"])
  B --> C(["Differentiate / shape"])
  C --> D(["Control the close"])
  A -.-> M(["MEDDIC"])
  B -.-> S(["SPIN · Solution selling"])
  C -.-> CH(["Challenger"])
  D -.-> M
Each method has a home zone in the deal, they overlap, but none of them does the whole job. Leaders Loop

SPIN: let the buyer make your argument for you

SPIN is the oldest of the four and the most rigorously evidenced. It comes from Neil Rackham's book SPIN Selling (McGraw-Hill, 1988), which was built on Huthwaite's analysis of more than 35,000 sales calls, at the time, the largest study of its kind. Rackham, a research psychologist by training, found that the closing tricks taught in most sales courses helped on small, low-value sales and actively hurt on large, complex ones.

What worked instead was a sequence of questions: Situation (the facts), Problem (where it hurts), Implication (what that pain costs if left alone), and Need-payoff (what solving it is worth). The Implication questions are the engine, they make a small irritation feel expensive enough to act on, in the buyer's own words rather than the seller's pitch.

Try this: in your next discovery call, ban yourself from pitching for the first twenty minutes. After the buyer names a problem, ask one more layer, "and when that happens, what does it knock on to?", before you say anything about your product. The buyer building the case out loud is far stickier than you building it for them.

Where SPIN stops short: it's a conversation skill, not a deal strategy. It tells you how to run a good meeting; it says nothing about whether the buyer can actually sign, or how to handle a six-person buying committee. Necessary, rarely sufficient.

Solution selling and Challenger: the argument that defined modern B2B sales

Solution selling, popularised by Michael Bosworth's Solution Selling: Creating Buyers in Difficult Selling Markets (1994) and later updated by Keith Eades, made consultative selling the default for a generation. The logic is intuitive: don't push a product, diagnose the customer's need and prescribe a tailored fix. For complex, intangible products it was a genuine advance over feature-dumping.

Then the ground shifted. In their 2011 book The Challenger Sale, and a widely-read companion article, "The End of Solution Sales" in Harvard Business Review (July–August 2012), Matthew Dixon and Brent Adamson of CEB argued that solution selling's core assumption had broken. Buyers now arrive having already googled, benchmarked and half-defined their own solution, then force suppliers into a price-driven bake-off. Asking "what keeps you up at night?" lands as a waste of their time.

Their study of around 6,000 reps across 90 companies sorted sellers into five profiles, the Hard Worker, the Relationship Builder, the Lone Wolf, the Reactive Problem Solver and the Challenger. The headline finding: in complex sales, Challengers dominated, accounting for roughly 40% of star performers, while Relationship Builders were the worst performers among the high-stakes group. The Challenger plays a "teach–tailor–take control" game: teach the customer something they didn't know about their own business, tailor it to each stakeholder, and assert control of the process.

Solution selling waits for the customer to name the problem. Challenger argues the customer often can't, so you have to reframe it for them.

Try this: before your next pitch, write one sentence the buyer doesn't already believe, a costly assumption in their current approach, backed by a number, and lead with that, not with discovery questions they've answered ten times. That's the Challenger "commercial insight" in practice.

The catch is real, though. Challenger's evidence is proprietary practitioner research, not independently replicated peer-reviewed work, and a provocative "teaching" stance can curdle into arrogance in the wrong hands or the wrong culture. It also fits transactional or relationship-driven markets far less well than the complex enterprise deals it was studied in. Treat the 40% figure as a credible signal from one large study, not a law of nature.

MEDDIC: the one that isn't about talking to buyers at all

MEDDIC is the odd one out, and the one most often misused. It's not a conversation technique, it's a qualification framework. It was built inside PTC (Parametric Technology Corporation) in the mid-1990s by Dick Dunkel and Jack Napoli, under sales leader John McMahon, after the company hired more reps and generated more leads but couldn't close proportionally more deals. The fix wasn't a better pitch, it was a sharper filter for which deals deserved attention.

The acronym is a checklist for every opportunity: Metrics (the quantified value), Economic buyer (who actually controls the budget), Decision criteria, Decision process, Identify pain, and Champion (an insider who sells for you when you're not in the room). The modern variant MEDDPICC adds Paper process (legal/procurement) and Competition. If you can't fill in those boxes, you don't have a deal, you have a hope.

Try this: at your next pipeline review, take your three biggest deals and ask one MEDDIC question, "who is the economic buyer, by name, and have we met them?" Deals where the answer is a shrug are the ones quietly slipping. MEDDIC's value is mostly in exposing the deals you should stop working.

And here's where it bites: MEDDIC is a scorecard, not a way to create demand or win a competitive fight. Lean on it too hard and reps become accountants of their own pipeline, great at forecasting, timid about pursuing the messy early-stage deals that don't qualify cleanly yet.

A worked example

Picture a rep selling a workforce-scheduling platform into a mid-sized hospital group. (Figures below are illustrative.) The buyer, a Director of Operations, opens with "we're looking at scheduling tools and want pricing on a 400-bed deployment." A solution-selling reflex says: great, run discovery, map features to needs. But the buyer has already defined the solution as "a scheduling tool," and three vendors are about to be compared on price.

The Challenger move is to refuse the framing. The rep opens with a teaching insight: "Most groups your size assume the cost is the scheduling software. In the deployments we've seen, roughly 70% of the avoidable cost is actually unplanned overtime caused by late roster changes, software that doesn't fix that just digitises the problem." Now the conversation is about a bigger, more expensive problem the buyer hadn't priced.

SPIN supplies the questions that make that real: How often do rosters change inside 48 hours? When they do, what's the overtime hit? If that ran another two years? The buyer does the arithmetic aloud, say, an illustrative $1.2m a year, and the deal is no longer a $90k software comparison.

MEDDIC then runs in the background as a cold check: Metrics, the $1.2m overtime number. Economic buyer, almost certainly the CFO, not the Director who took the meeting. Champion, is the Director willing to walk this to finance? If MEDDIC says "no economic buyer, no champion," the rep keeps the deal in early stage and doesn't forecast it, however good the conversation felt. One deal; four frameworks; four distinct jobs.

flowchart TD
  A(["Buyer asks for pricing on a 'scheduling tool'"]) --> B(["Challenger: reframe, the real cost is unplanned overtime"])
  B --> C(["SPIN: questions size the pain in the buyer's own numbers"])
  C --> D(["MEDDIC: is there an economic buyer and a champion?"])
  D --> E(["Forecast only if it qualifies"])
One deal moving through all four lenses, reframe, size, qualify, then commit to the forecast. Leaders Loop

Frequently asked questions

Which methodology should we standardise on?

Most effective sales organisations don't pick one, they stack a qualification framework (usually MEDDIC/MEDDPICC) with a conversation method (SPIN, or a Challenger-style teaching motion). The qualification layer keeps the pipeline honest; the conversation layer wins the meetings. Forcing a single framework to do both jobs is where teams get into trouble.

Is solution selling dead, as Challenger claimed?

No, "The End of Solution Sales" was a deliberately provocative title. Consultative diagnosis still works when the buyer genuinely doesn't know what they need. Challenger's real point is narrower: in commoditised, well-researched markets, waiting for the buyer to define the problem cedes control. Where demand is established, diagnose; where it's emerging, teach.

Does the Challenger research actually hold up?

Treat it as strong practitioner evidence rather than settled science. The CEB study was large (around 6,000 reps) and its conclusions are widely used, but it's proprietary research, not independently replicated peer-reviewed work. SPIN's evidence base, 35,000+ analysed calls, is the more rigorous of the two. Useful, both; infallible, neither.

We're a small or early-stage team. Is this overkill?

Start with the cheapest, highest-leverage piece: SPIN-style questioning so reps stop pitching too early, and the two MEDDIC questions that matter most, "who signs?" and "who's our champion?". You don't need the full apparatus to get most of the benefit. Add structure as the deals (and the committee sizes) grow.

How does this fit with a defined sales process?

A methodology is how you sell; a sales process is the stages a deal passes through. MEDDIC fields become the exit criteria for each stage, and SPIN/Challenger are the behaviours inside them. See sales process & pipeline management for how the two layers connect.

Related in the Toolkit

Where to go next